Steve Kafka

Steve Kafka, Ph.D., is a Managing Partner of Section 32 and serves as Executive Chairman of ArcherDx. A passion for working with exceptional scientists and creative business executives, Steve has helped to build multiple companies that focus on transformative impact for patient care, present rewarding professional opportunities for employees, and deliver outstanding investor returns.

Prior to Section 32, Steve was a venture partner and partner at Third Rock Ventures, where he helped build and served as the initial CEO of Thrive Earlier Detection, a healthcare company that develops early detection tests for multiple types of cancer. Steve is currently also executive chairman of Thrive. Previously, Steve was President and Chief Operating Officer of Foundation Medicine, a company that pioneered comprehensive genomic profiling services for patients with cancer; Foundation Medicine was acquired by Roche in 2018.

Steve has also held executive leadership roles with several biopharmaceutical companies, including Millennium Pharmaceuticals, Infinity Pharmaceuticals and Aileron Therapeutics.

Steve holds a Ph.D. degree in political economy and government from Harvard University and a BA degree in economics and political science from Stanford University.